Future directions in research with presymptomatic individuals carrying the gene for Huntington's disease

Brain Research Bulletin

Volumn 59, Issue 5, 2003, Pages 331-338

  Georgiou Karistianis, Nellie ^a   Smith, Eleanor ^a   Bradshaw, John L ^a   Chua, Phyllis ^b   Lloyd, John ^b   Churchyard, Andrew ^c   Chiu, Edmond ^d  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

^d ST GEORGE HOSPITAL   (Australia)

Author keywords

Disease onset; Ethical issues; Huntington's disease; Presymptomatic gene carriers; Therapeutic intervention

Indexed keywords

COGNITIVE DEFECT; DISEASE COURSE; GENE; HUMAN; HUNTINGTON CHOREA; MEDICAL ETHICS; MOOD DISORDER; MOTOR PERFORMANCE; ONSET AGE; PRIORITY JOURNAL; RESEARCH; REVIEW;

AGE OF ONSET; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; HUNTINGTON DISEASE;

EID: 0037472335     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(02)00877-8     Document Type: Review

References (100)

1. De Boo G.M., Tibben A., Lanser J.B., Jennekens-Schinkel A., Hermans J., Maat-Kievit A., Roos R.A.C. Early cognitive and motor symptoms in identified carriers of the gene for Huntington disease. Arch. Neurol. 54:1997;1353-1357.
2. Conneally P.M. Huntington disease: Genetics and epidemiology. Am. J. Hum. Genet. 36:1984;506-526.
3. Bradshaw, J. L.; Mattingley, J. B. Clinical neuropsychology: Behavioural and brain science. London: Academic Press; 1995.
4. Gomez-Tortosa E., MacDonald M.E., Friend J.C., Taylor S.A., Weiler L.J., Cupples L.A., Srinidhi J., Gusella J.F., Bird E.D., Vonsattel J.P., Myers R.H. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann. Neurol. 49:2001;29-34.
5. Gusella, J. F.; Wexler, N. S.; Conneally, P. M.; Naylor, S. L.; Anderson, M. A.; Tanzi, R. E.; Watkins, P. C.; Ottina, K.; Wallace, M. R.; Sakaguchi, A. Y.; et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306:234-238; 1983.
6. Zechner U., Scheel S., Hemberger M., Hopp M., Haaf T., Fundele R., Wanker E.E., Lehrach H., Wedemeyer N., Himmelbauer H. Characterization of the mouse Src homology 3 domain gene Sh3d2c on Chr 7 demonstrates coexpression with huntingtin in the brain and identifies the processed pseudogene Sh3d2c-ps1 on Chr 2. Genomics. 54:1998;505-510.
7. Engelender S., Sharp A.H., Colomer V., Tokito M.K., Lanahan A., Worley P., Holzbaur E.L., Ross C.A. Huntingtin-associated protein 1 (HAP1) interacts with the p150Glued subunit of dynactin. Hum. Mol. Genet. 6:1997;2205-2212.
8. Sathasivam K., Amaechi I., Mangiarini L., Bates G. Identification of an HD patient with a (CAG)180 repeat expansion and the propagation of highly expanded CAG repeats in lambda phage. Hum. Genet. 99:1997;692-695.
9. Nance M.A. Huntington disease - Another chapter rewritten. Am. J. Hum. Genet. 59:1996;16.
10. Rubinsztein D.C., Leggo J., Chiano M., Dodge A., Norbury G., Rosser E., Craufurd D. Genotypes at the GluR6 receptor locus are associated with variation in the age of onset of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3872-3876.
11. Foroud T., Gray J., Ivashina J., Conneally M.P. Differences in duration of Huntington's disease based on age at onset. J. Neurol. Neurosurg. Psychiatry. 66:1999;52-56.
12. DiFiglia M. Clinical genetics, II. Huntington's disease: From the gene to pathophysiology. Am. J. Psychiatry. 154:1997;1046.
13. MacDonald M.E., Barnes G., Srinidhi J., Duyao M.P., Ambrose C.M., Myers R.H., Gray J., Conneally P.M., Young A., Penney J.et al. Gametic but not somatic instability of CAG repeat length in Huntington's disease. J. Med. Genet. 30:1993;982-986.
14. McCusker E., Richard F., Sillence D., Wilson M., Trent R.J. Huntington's disease: Neurological assessment of potential gene carriers presenting for predictive DNA testing. J. Clin. Neurosci. 7:2000;38-41.
15. Roos R.A.C., Vegter-van der Vlis M., Hermans J. Age at onset in Huntington's disease: Effect of line of inheritance and patient's sex. J. Med. Genet. 28:1991;515-519.
16. Myers, R. H.; Marans, K. S.; MacDonald, M. E. Huntington's disease. In: Wells, R. D.; Warren, S. T.; Sarmiento, M., eds. Genetic instabilities and hereditary neurological diseases. New York: Academic Press; 1998:301-323.
17. Gusella J.F., MacDonald M.E. Huntington's disease. Semin. Cell Biol. 6:1995;21-28.
18. Andrew S.E., Goldberg Y.P., Kremer B. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 4:1993;398-403.
19. Brinkman R.R., Mezei M.M., Theilmann J., Almqvist E., Hayden M.R. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am. J. Hum. Genet. 60:1997;1202-1210.
20. Duyao M., Ambrose C., Myers R., Novelletto A., Persichetti F., Frontali M., Folstein S., Ross C., Franz M., Abbott M.et al. Trinucleotide repeat length instability and age of onset in Huntington disease. Nat. Genet. 4:1993;387-392.
21. Snell R.G., MacMillan J.C., Cheadle J.P., Fenton I., Lazarou L.P., Davies P., MacDonald M.E., Gusella J.F., Harper P.S., Shaw D.J. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 4:1993;393-397.
22. Merritt, A. D., Conneally, P. M., Rahman, N. F., Drew, A. L. Juvenile Huntington's chorea. In: Barbeau, A.; Brunette, J. R., eds. Progress in Neurogenetics. Amsterdam: Excerpta Medica Foundation, 1969:645-650.
23. Bird E.D., Caro A.J., Pilling J.B. A sex related factor in the inheritance of Huntington's chorea. Ann. Hum. Genet. 37:1974;255-260.
24. Ranen N.G., Stine O.C., Abbott M.H., Sherr M., Codori A.M., Franz M.L., Chao N.I., Chung A.S., Pleasant N., Callahan C.et al. Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington's disease. Am. J. Hum. Genet. 57:1995;593-602.
25. Trottier Y., Biancalana V., Mandel J.L. Instability of CAG repeats in Huntington's disease: Relation to parental transmission and age of onset. J. Med. Genet. 31:1993;377-382.
26. Topper R., Schwarz M., Lange H.W., Hefter H., Noth J. Neurophysiological abnormalities in the Westphal variant of Huntington's disease. Mov. Disord. 13:1998;920-928.
27. Leeflang E.P., Zhang L., Tavare S., Hubert R., Srinidhi J., MacDonald M.E., Myers R.H., de Young M., Wexler N.S., Gusella J.F.et al. Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: Quantification of the mutation frequency spectrum. Hum. Mol. Genet. 4:1995;1519.
28. Aylward E.H., Codori A.M., Barta P.E., Pearlson G.D., Harris G.J., Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch. Neurol. 53:1996;1293-1296.
29. Campodonico J.R., Codori A.M., Brandt J. Neuropsychological stability over 2 years in asymptomatic carriers of the Huntington's disease mutation. J. Neurol. Neurosurg. Psychiatry. 61:1996;621-624.
30. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., Ffrench-Constant C., Rubinsztein D.C., Robbins T.W., Sahakian B.J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain. 121:1998;1329-1341.
31. Claes S., Van Zand K., Legius E., Dom R., Malfroid M., Baro F., Godderis J., Cassiman J. Correlations between triplet repeat expansion and clinical features in Huntington's disease. Arch. Neurol. 52:1995;749-753.
32. Vuillaume I., Vermersch P., Destee A., Petit H., Sablonniere B. Genetic polymorphisms adjacent to the CAG repeat influence clinical features at onset in Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 64:1998;758-762.
33. Furtado S., Suchowersky O., Rewcastle N.B., Graham L., Klimek M.L., Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann. Neurol. 39:1996;132-136.
34. Penney J.B., Vonsattel J.P., MacDonald M.E., Gusella J.F., Myers R.H. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol. 41:1997;689-692.
35. Xuereb J.H., MacMillan J.C., Snell R., Davies P., Harper P.S. Neuropathological diagnosis and CAG repeat expansion in Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 60:1996;78-81.
36. Antonini A., Leenders K.L., Eidelberg D. [1C]Raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length. Ann. Neurol. 43:1998;253-255.
37. Illarioshkin S.N., Igarashi S., Onodera O., Markova E.D., Nikolskaya N.N., Tanaka H., Chabrashwili T.Z., Insarova N.G., Endo K., Ivanova-Smolenskaya I.A.et al. Trinucleotide repeat length and rate of progression of Huntington's disease. Ann. Neurol. 36:1994;630-635.
38. Brandt J., Bylsma F.W., Gross R., Stine O.C., Ranen N., Ross C.A. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology. 46:1996;527-531.
39. Lucotte G., Turpin J.C., Riess O., Epplen J.T., Siedlaczk I., Loirat F., Hazout S. Confidence intervals for predicted age of onset, given the size of the (CAG)n repeat, in Huntington's disease. Hum. Genet. 92:1995;231-232.
40. Kieburtz K., MacDonald M., Shih C., Feigin A., Steinberg K., Bordwell K., Zimmerman C., Srinidhi J., Sotack J., Gusella J.et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J. Med. Genet. 31:1994;872-874.
41. Currier R.D., Jackson J.F., Meydrech E.F. Progression rate and age at onset are related in autosomal dominant neurological diseases. Neurology. 32:1982;907-909.
42. Shoulson I., Fahn S. Huntington disease: Clinical care and evaluation. Neurology. 29:1979;1-3.
43. Feigin A., Kieburtz K., Bordwell K., Como P., Steinberg K., Sotack J., Zimmerman C., Hickey C., Orme C., Shoulson I. Functional decline in Huntington's disease. Mov. Disord. 10:1995;211-214.
44. Myers R.H., Sax D.S., Koroshetz W.J., Mastromauro C., Cupples L.A., Kiely D.K., Pettengill F.K., Bird E.D. Factors associated with slow progression in Huntington's disease. Arch. Neurol. 48:1991;800-804.
45. Folstein, S. E. Huntington's disease: A disorder of families. Baltimore, MD: Johns Hopkins University Press; 1989.
46. Marder K., Zhao H., Myers R.H., Cudkowicz M., Kayson E., Kieburtz K., Orme C., Paulsen J., Penny J.B. Jr., Siemers E., Shoulson I. Rate of functional decline in Huntington's disease. Neurology. 54:2000;452-458.
47. Harper, P. S., ed. Huntington's disease, 2nd ed. London: Saunders; 1996.
48. Myers R.H., Madden J.H., Teague J.L., Falek E.I. Factors related to onset age in Huntington's disease. Am. J. Hum. Genet. 34:1982;481-488.
49. Roos R.A., Hermans J., Vegter-van der Vlis M., van Ommen G.J., Bruyn G.W. Duration of illness in Huntington's disease is not related to age at onset. J. Neurol. Neurosurg. Psychiatry. 56:1993;98-100.
50. Hahn-Barma V., Deweer B., Durr A., Dode C., Feingold J., Pillon B., Agid Y., Brice A., Dubois B. Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. J. Neurol. Neurosurg. Psychiatry. 64:1998;172-177.
51. Foroud T., Siemers E., Kleindorfer D., Bill D.J., Hodes M.E., Norton J.A., Conneally P.M., Christian J.C. Cognitive scores in carriers of Huntington's disease gene compared to noncarriers. Ann. Neurol. 37:1995;657-664.
52. Kirkwood S.C., Siemers E., Stout J.C., Hodes M.E., Conneally P.M., Christian J.C., Foroud T. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch. Neurol. 56:1999;563-568.
53. Huntington Study Group. Unified Huntington's Disease Rating Scale: Reliability and consistency. Mov. Disord. 11:136-142; 1996.
54. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57:1998;369-384.
55. Hedreen J.C., Folstein S.E. Early loss of neostriatal neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 54:1995;105-120.
56. Richfield E.K., Maguire-Zeiss K.A., Cox C., Gilmore J., Voorn P. Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. Ann. Neurol. 37:1995;335-343.
57. Joel D. Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease. Mov. Disord. 16:2001;407-423.
58. Andrews T.C., Weeks R.A., Turjanski N., Gunn R.N., Watkins L.H.A., Sahakian B., Hodges J.R., Rosser A.E., Wood N.W., Brooks D.J. Huntington's disease progression: PET and clinical observations. Brain. 122:1999;2353-2363.
59. Campodonico J.R., Aylward E., Codori A., Young C., Krafft L., Magdalinski M., Ranen N. When does Huntington's disease begin? J. Int. Neuropsychol. Soc. 4:1998;467-473.
60. Antonini A., Leenders K.L., Spiegel R., Meier D., Vontobel P., Weigell-Weber M., Sanchez-Pernaute R., de Yebebez J.G., Boesiger P., Weindl A., Maguirem R.P. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain. 119:1996;2085-2095.
61. Grafton S.T., Mazziotta J.C., Pahl J.J., St George-Hyslop P., Haines J.L., Gusella J., Hoffman J.M., Baxter L.R., Phelps M.E. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch. Neurol. 49:1992;1161-1167.
62. Hussey D., Stewart D., Houle S., Guttman M. [c-11] raclopride striatal binding potential as a measure of Huntington's disease progression: Implications for prospective neuroprotective studies. J. Nucl. Med. 39(suppl.):1998;209P.
63. Kirkwood S.C., Siemers E., Bond C., Coneally P.M., Christian J.C., Foroud T. Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch. Neurol. 57:2000;1040-1044.
64. Rosenberg N.K., Sorensen S.A., Christensen A. Neuropsychological characteristics of Huntington's disease carriers: A double blind study. J. Med. Genet. 32:1995;600-604.
65. Diamond R., White R.F., Myers R.H., Mastromauro C., Koroshetz W.J., Butters N., Rothstein D.M., Moss M.B., Vasterling J. Evidence of presymptomatic cognitive decline in Huntington's disease. J. Clin. Exp. Neuropsychol. 14:1992;961-975.
66. Jason G.W., Suchowersky O., Pajurkova E.M., Graham L., Klimek M.L., Garber A.T., Poirier-Heine D. Cognitive manifestations of Huntington disease in relation to genetic structure and clinical onset. Arch. Neurol. 54:1997;1081-1087.
67. Wechsler, D. Weschler Adult Intelligence Scale-Revised. New York: Psychological Corporation; 1981.
68. De Boo G.M., Tibben A., Hermans J., Jennekens-Schinkel A., Maat-Kievit A., Roos R.A.C. Memory and learning are not impaired in presymptomatic individuals with an increased risk of Huntington's disease. J. Clin. Exp. Neuropsychol. 21:1999;831-836.
69. Giordani B., Berent S., Boivin M.J., Penney J.B., Lehtinen S., Markel D.S., Hollingsworth Z., Butterbaugh G., Hichwa R.D., Gusella J.F. Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. Arch. Neurol. 52:1995;59-64.
70. Paulsen J.S., Zhao H., Stout J.C., Brinkman R.R., Guttman M., Ross C.A., Como P., Manning C., Hayden M.R., Shoulson I. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology. 57:2001;658-662.
71. Smith M.A., Brandt J., Shadmehr R. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature. 403:2000;544-549.
72. Siemers E., Foroud T., Bill D.J., Sorbel J., Norton J.A.J., Hodes M.E., Niebler G., Conneally P.M., Christian J.C. Motor changes in presymptomatic Huntington disease gene carriers. Arch. Neurol. 5:1996;487-492.
73. Blackmore L., Simpson S.A., Crawford J.R. Cognitive performance in UK sample of presymptomatic people carrying the gene for Huntington's disease. J. Med. Genet. 32:1995;358-362.
74. Gomez-Tortosa E., del Barrio A., Barroso T., Garcia Ruiz P.J. Visual processing disorders in patients with HD and asymptomatic carriers. J. Neurol. 243:1996;286-292.
75. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 134:1979;382-389.
76. Covi L., Lipman R.S. Primary depression or primary anxiety? A possible psychometric approach to a diagnostic dilemma. Clin. Neuropharmacol. 7:1984;924-925.
77. Pollock V., Cho D.W., Reker D., Volavka J. Profile of Mood States: The factors and their physiological correlates. J. Nerv. Ment. Dis. 167:1979;612-614.
78. Shiwach R.S., Norbury C.G. A controlled psychiatric study of individuals at risk for Huntington's disease. Br. J. Psychiatry. 165:1994;500-505.
79. Pirozzolo, F. J.; Swihart, A. A.; Rey, G. J.; Mahurin, R.; Jankovic, J. Cognitive impairments associated with Parkinson's disease and other movement disorders. In: Jankovic, J.; Tolosa, E., eds. Parkinsons's disease and movement disorders, 2nd ed. Baltimore: Williams & Wilkins; 1993:493-510.
80. Evers-Kieboom G., Swerts A., Cassiman J.J., Van den Berghe H. The motivation of at risk individuals and their partners in deciding for or against predictive testing for Huntington's disease. Clin. Genet. 35:1989;29-40.
81. Simpson S.A., Besson J., Alexander D., Allan K., Johnston A.W. One hundred requests for presymptomatic testing in Huntington's disease. Clin. Genet. 41:1992;326-330.
82. World Federation of Neurology Research Group on Huntington's Disease. Presymptomatic testing for Huntington's disease: A world-wide survey. J. Med. Genet. 30:1020-1022; 1993.
83. Maat-Kievit A., Vegter-van der Vlis M., Zoeteweij M., Losekoot M., van Haeringen A., Roos R. Paradox of a better test for Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 69:2000;579-583.
84. Maat-Kievit A., Vegster-van der Vlis M., Zoeteweij M., Losekoot M., van Haeringen A., Kanhaj H., Roos R. Experience in prenatal testing for Huntington's disease in the Netherlands: Procedures, results and guidelines (1987-1997). Prenat. Diagn. 19:1999;450-457.
85. Di Maio L., Squitieri F., Napolitano G., Campanella G., Trofatter J.A., Conneally P.M. Suicide risk in Huntington's disease. J. Med. Genet. 30:1993;293-295.
86. European Community Huntington's Disease Collaborative Study Group. Ethical and social issues in presymptomatic testing for Huntington's Disease: A European Community Collaborative Study. J. Med. Genet. 30:1028-1035; 1993.
87. Binedell J., Soldan J.R., Scourfield J., Harper P.S. Huntington's disease predictive testing: The case for an assessment approach to requests from adolescents. J. Med. Genet. 33:1996;912-918.
88. Clark, C. M.; Trojanowski, J. Q., eds. Neurodegenerative dementias: Clinical features and pathological mechanisms. New York: McGraw-Hill; 2000.
89. Wexler N.S. The Tiresias complex: Huntington's disease as a paradigm of testing for late onset disorders. FASEB J. 6:1992;2820-2825.
90. Bachoud-Levi A.C., Remy P., Nguyen J.P., Brugieres P., Lefaucheur J.P., Bourdet C., Baudic S., Gaura V., Maison P., Haddad B., Boisse M.F., Grandmougin T., Jeny R., Bartolomeo P., Dalla Barba G., Degos J.D., Lisovoski F., Ergis A.M., Pailhous E., Cesaro P., Hantraye P., Peschanski M. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet. 9(356):2000;1975-1979.
91. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6:2000;797-801.
92. Kremer B., Clark C.M., Almqvist E.W., Raymond L.A., Graf P., Jacova C., Mezei M., Hardy M.A., Snow B., Martin W., Hayden M.R. Influence of lamotrigine on progression of early Huntington disease: A randomized clinical trial. Neurology. 2(53):1999;1000-1011.
93. Rosas H.D., Koroshetz W.J., Jenkins B.G., Chen Y.I., Hayden D.L., Beal M.F., Cudkowicz M.E. Riluzole therapy in Huntington's disease HD. Mov. Disord. 14:1999;326-330.
94. Peyser C.E., Folstein M., Chase G.A., Starkstein S., Brandt J., Cockrell J.R., Bylsma F., Coyle J.T., McHugh P.R., Folstein S.E. Trial of d-alpha-toco-pherol in Huntington's disease. Am. J. Psychol. 152:1995;1771-1775.
95. Ranen N.G., Peyser C.E., Coyle J.T., Bylsma F.W., Sherr M., Day L., Folstein M.F., Brandt J., Ross C.A., Folstein S.E. A controlled trial of idebenone in Huntington's disease. Mov. Disord. 11:1996;549-554.
96. Ashizawa, T. New treatment strategies. Huntington's Disease Workshop, Houston, TX, 2/16/96. Source: world wide web, URL: http://www.bcm.tmc.edu/neurol/index.html.
97. Nakao N., Grasbon-Frodl E., Widner H., Brundin P. Antioxidant treatment protects striatal neurons against excitotoxic insults. Neuroscience. 73:1996;185.
98. Koroshetz W.J., Jenkins B.G., Rosen B.R., Beal M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41:1997;160-165.
99. Andrews, T. C.; Brooks, D. J. Advances in the understanding of early Huntington's Disease using the functional imaging techniques of PET and SPET. Mol. Med. Today. 4:532-539; 1998.
100. Ross C.A., Margolis R.L. Huntington's disease. Clin. Neurosci. Res. 1:2001;142-152.